Etzerodt et al. developed an anti-CD163 IgG mAb conjugated with lipid nanoparticles loaded with the cytotoxic agent doxorubicin.109 In a mouse model of BRAF-mutant melanoma, the group demonstrated that the antibody was able to deplete CD163+ TAMs and this depletion led to an almost complete inhibition of tumor growth, which was more effective than pan-TAM blockade using CSF1R and CCR2 inhibition. This evidence concerns the gene CD163 and melanoma.